FilingReader Intelligence
Huahai Pharmaceutical subsidiary gets priority drug review
August 18, 2025 at 05:13 PM UTC•By FilingReader AI
Shanghai Hua Ao Tai Biotechnology's HB0034 injection for generalized pustular psoriasis has received priority review from China's drug regulator, qualifying as a breakthrough therapeutic drug.
Zhejiang Huahai Pharmaceutical's subsidiary has invested RMB 22.45bn in the project. The drug also holds orphan drug designation from the US FDA.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
News Alerts
Get instant email alerts when Zhejiang Huahai Pharmaceutical publishes news
Free account required • Unsubscribe anytime